Aditum Bio Breaks New Ground with Celexor Bio: Pioneering Cell Depletion for Tackling Autoimmune and Inflammatory Disorders

OAKLAND, Calif., Sept. 21, 2023 /PRNewswire/ — Aditum Bio, the brainchild of former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman, continues its trailblazing journey with the formation of Celexor Bio, its tenth groundbreaking venture.

Celexor Bio is poised to revolutionize the realm of inflammatory disorders, driven by a potent depleting antibody that zeroes in on immunoglobulin-like transcript 7 (ILT7)—a highly specific cell surface marker residing on plasmacytoid dendritic cells (pDCs). This game-changing compound (IMG-018), soon to be renamed CLXR-901, is set to close its licensing deal with Inmagene Biopharmaceuticals later this month.

The story unfolds with pDCs, a specialized subtype of dendritic cells renowned for their ability to unleash a torrent of Type I interferons and pro-inflammatory cytokines. These cells have long been implicated in the pathogenesis of various autoimmune and inflammatory maladies. Enter CLXR-901, a swift and potent eliminator of these rogue cells, offering a beacon of hope for individuals grappling with severe autoimmune and inflammatory disorders.

Joe Jimenez, Co-Founder and Managing Director of Aditum Bio, champions the unique incubator model that powers their quest. “Aditum Bio’s unique incubator model enables us to accelerate the development of novel medicines, and we look forward to bringing this promising therapy to patients in need,” he exclaims.

Dr. Mark Fishman, Co-Founder and Chair of the Medical and Scientific Advisory Boards, emphasizes the pivotal role pDCs play in the pathophysiology of multiple disorders. With CLXR-901’s direct assault on these pathological cells, it could herald a new era of safety and efficacy in treating these daunting conditions.

Celexor Bio joins Aditum Bio’s illustrious portfolio, aligning with their unwavering mission—to provide access to essential medicines for large patient populations that might otherwise remain underserved. Aditum Bio’s incubator model injects agility into drug development, focusing on the crucial translational phase.

This dynamic “spin out” approach fosters a start-up culture, bolstered by a dedicated team and Aditum’s cadre of operational and technical experts, spanning nonclinical pharmacology, CMC, regulatory affairs, and clinical operations. The future holds great promise as Celexor Bio takes the lead in conquering inflammatory disorders.

About Aditum Bio

At Aditum Bio, the mission is crystal clear: to reshape public health through the swift advancement of research and development in areas that touch the lives of many. Their vision extends across a spectrum—from the vast landscapes of diseases impacting large populations to the intricate niches of more specialized conditions. It’s where medical innovation can wield its greatest transformative power.

The secret sauce, Aditum Bio’s unwavering focus on the very mechanisms that underpin these diseases. They hunt for promising drug candidates that zero in on these pathophysiological triggers. But here’s where the magic happens: Aditum Bio doesn’t just stop at discovery. They take these medical gems and breathe life into them through a remarkable process. Each potential game-changer gets its own dedicated company, primed to navigate the intricate journey through clinical trials.

Aditum Bio isn’t just rewriting the rules of health—it’s authoring a whole new chapter in the book of medical progress, one breakthrough at a time.

About Inmagene Biopharmaceuticals

Inmagene isn’t just another biotech company—it’s a global powerhouse on a mission to transform the landscape of immunological and inflammatory diseases. With an impressive portfolio boasting four clinical assets and a preclinical pipeline teeming with innovation, Inmagene is at the forefront of therapeutic breakthroughs.

Picture this: cutting-edge clinical assets like IMG-007, armed with an extended half-life and a silenced ADCC function, or IMG-004, a BTK inhibitor with remarkable longevity and pharmacodynamic prowess. Not to forget the game-changing IMG-008, a long-acting anti-IL-36R monoclonal antibody. These are the heroes battling the most challenging health adversaries.

But that’s not all. Inmagene is all about collaboration and global impact. Alongside its partners, it’s co-developing IMG-020—izokibep, an anti-IL-17 fusion protein. What’s remarkable is that Inmagene holds not only global potential but also exclusive development and commercialization rights in select Asian regions.

Inmagene isn’t just rewriting the future of healthcare; it’s penning an extraordinary narrative of health, innovation, and global impact.

Leave a Comment